MD3475303T2 - Formulări de anticorp anti-CD19 - Google Patents
Formulări de anticorp anti-CD19 Download PDFInfo
- Publication number
- MD3475303T2 MD3475303T2 MDE20190533T MDE20190533T MD3475303T2 MD 3475303 T2 MD3475303 T2 MD 3475303T2 MD E20190533 T MDE20190533 T MD E20190533T MD E20190533 T MDE20190533 T MD E20190533T MD 3475303 T2 MD3475303 T2 MD 3475303T2
- Authority
- MD
- Moldova
- Prior art keywords
- antibody formulations
- antibody
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16176322 | 2016-06-27 | ||
| PCT/EP2017/065819 WO2018002031A1 (en) | 2016-06-27 | 2017-06-27 | Anti-cd19 antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3475303T2 true MD3475303T2 (ro) | 2021-09-30 |
Family
ID=56368805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20190533T MD3475303T2 (ro) | 2016-06-27 | 2017-06-27 | Formulări de anticorp anti-CD19 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11352423B2 (enExample) |
| EP (2) | EP3909985A1 (enExample) |
| JP (3) | JP2019524671A (enExample) |
| KR (2) | KR102533875B1 (enExample) |
| CN (2) | CN115998859A (enExample) |
| AU (2) | AU2017289085B2 (enExample) |
| CA (1) | CA3029137A1 (enExample) |
| CY (1) | CY1124521T1 (enExample) |
| DK (1) | DK3475303T3 (enExample) |
| ES (1) | ES2874640T3 (enExample) |
| HR (1) | HRP20210945T1 (enExample) |
| HU (1) | HUE054296T2 (enExample) |
| IL (1) | IL263764B2 (enExample) |
| LT (1) | LT3475303T (enExample) |
| MA (1) | MA45450B1 (enExample) |
| MD (1) | MD3475303T2 (enExample) |
| MX (1) | MX2018016362A (enExample) |
| PL (1) | PL3475303T3 (enExample) |
| PT (1) | PT3475303T (enExample) |
| RS (1) | RS62035B1 (enExample) |
| RU (1) | RU2748024C2 (enExample) |
| SG (2) | SG10201912369QA (enExample) |
| SI (1) | SI3475303T1 (enExample) |
| SM (1) | SMT202100317T1 (enExample) |
| WO (1) | WO2018002031A1 (enExample) |
| ZA (1) | ZA201900483B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| LT3532098T (lt) | 2016-10-28 | 2021-06-25 | Morphosys Ag | Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| AU2020372646A1 (en) | 2019-10-31 | 2022-05-12 | Incyte Corporation | Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells |
| JP2023530499A (ja) | 2020-06-22 | 2023-07-18 | モルフォシス・アーゲー | 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法 |
| AU2021357841A1 (en) | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
| WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
| EP4426439A1 (en) | 2021-11-03 | 2024-09-11 | Affimed GmbH | Bispecific cd16a binders |
| AU2023264582A1 (en) * | 2022-05-03 | 2024-11-21 | Incyte Corporation | Methods for treating lymphoma |
| EP4572756A1 (en) | 2022-08-17 | 2025-06-25 | Incyte Corporation | Therapy comprising anti-cd19 antibody and ezh2 modulators |
| IL322510A (en) * | 2023-03-02 | 2025-10-01 | Novetide Ltd | Method for preparing GLP-1 peptides with controlled particle size |
| CN120754244B (zh) * | 2025-09-10 | 2025-12-12 | 江苏豪森药业集团有限公司 | 一种含抗cd19抗体的药物组合物及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| PT1966245E (pt) | 2005-12-30 | 2011-08-31 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
| RS53263B (sr) * | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| KR101456728B1 (ko) | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| LT2176298T (lt) | 2007-05-30 | 2018-04-10 | Xencor, Inc. | Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2010095031A2 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| JP2012519712A (ja) * | 2009-03-06 | 2012-08-30 | メディミューン，エルエルシー | ヒト化抗ｃｄ１９抗体製剤 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| WO2014160490A1 (en) | 2013-03-13 | 2014-10-02 | Genetech, Inc. | Antibody formulations |
| RU2707092C2 (ru) | 2013-03-13 | 2019-11-22 | Дженентек, Инк. | Составы со сниженным окислением |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| LT3049441T (lt) | 2013-09-27 | 2020-02-10 | F. Hoffmann-La Roche Ag | Anti-pdl1 antikūnų kompozicija |
| JP6590803B2 (ja) * | 2013-11-21 | 2019-10-16 | ゲンマブ エー／エス | 抗体−薬物コンジュゲート凍結乾燥製剤 |
| CA2942150A1 (en) * | 2014-04-07 | 2015-10-15 | Seattle Genetics, Inc. | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
-
2017
- 2017-06-27 HR HRP20210945TT patent/HRP20210945T1/hr unknown
- 2017-06-27 PL PL17735440T patent/PL3475303T3/pl unknown
- 2017-06-27 US US16/310,555 patent/US11352423B2/en active Active
- 2017-06-27 EP EP21167818.0A patent/EP3909985A1/en active Pending
- 2017-06-27 RU RU2019100221A patent/RU2748024C2/ru active
- 2017-06-27 KR KR1020197002043A patent/KR102533875B1/ko active Active
- 2017-06-27 MD MDE20190533T patent/MD3475303T2/ro unknown
- 2017-06-27 MX MX2018016362A patent/MX2018016362A/es unknown
- 2017-06-27 DK DK17735440.4T patent/DK3475303T3/da active
- 2017-06-27 CN CN202211458395.0A patent/CN115998859A/zh active Pending
- 2017-06-27 WO PCT/EP2017/065819 patent/WO2018002031A1/en not_active Ceased
- 2017-06-27 SG SG10201912369QA patent/SG10201912369QA/en unknown
- 2017-06-27 CA CA3029137A patent/CA3029137A1/en active Pending
- 2017-06-27 LT LTEP17735440.4T patent/LT3475303T/lt unknown
- 2017-06-27 PT PT177354404T patent/PT3475303T/pt unknown
- 2017-06-27 KR KR1020237016157A patent/KR20230074823A/ko not_active Ceased
- 2017-06-27 MA MA45450A patent/MA45450B1/fr unknown
- 2017-06-27 RS RS20210748A patent/RS62035B1/sr unknown
- 2017-06-27 AU AU2017289085A patent/AU2017289085B2/en active Active
- 2017-06-27 SG SG11201810429UA patent/SG11201810429UA/en unknown
- 2017-06-27 SI SI201730801T patent/SI3475303T1/sl unknown
- 2017-06-27 JP JP2018567742A patent/JP2019524671A/ja active Pending
- 2017-06-27 ES ES17735440T patent/ES2874640T3/es active Active
- 2017-06-27 IL IL263764A patent/IL263764B2/en unknown
- 2017-06-27 CN CN201780039737.6A patent/CN109415440B/zh active Active
- 2017-06-27 HU HUE17735440A patent/HUE054296T2/hu unknown
- 2017-06-27 SM SM20210317T patent/SMT202100317T1/it unknown
- 2017-06-27 EP EP17735440.4A patent/EP3475303B1/en active Active
-
2019
- 2019-01-23 ZA ZA2019/00483A patent/ZA201900483B/en unknown
-
2021
- 2021-06-14 CY CY20211100532T patent/CY1124521T1/el unknown
-
2022
- 2022-03-22 US US17/700,809 patent/US20220213190A1/en active Pending
- 2022-05-18 JP JP2022081779A patent/JP7603201B2/ja active Active
-
2024
- 2024-05-23 JP JP2024083988A patent/JP2024109816A/ja active Pending
- 2024-07-24 AU AU2024205042A patent/AU2024205042A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272227A (en) | Anti-tigit antibodies | |
| IL263764A (en) | Anti-cd19 antibody formulations | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3498840A4 (en) | ANTI-LAG-3 ANTIBODIES | |
| PT3606954T (pt) | Anticorpos anti-lag3 | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| DK3411404T3 (da) | Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner | |
| DK3504241T3 (da) | Anti-cd3-antistofformuleringer | |
| HUE051700T2 (hu) | Anti-PD-1 antitestek | |
| EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
| PT3354729T (pt) | Anticorpo anti-garp | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| DK3484446T3 (da) | Antistofsammensætninger | |
| IL256099A (en) | Antibody | |
| DK3481420T3 (da) | Antistofformuleringer | |
| EP3579879A4 (en) | ANTI-BODY ANTI-KIR3DL1 | |
| DK3452515T3 (da) | Her-2-bindende antistoffer | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer | |
| EP3720492A4 (en) | ANTI-RSPO3 ANTIBODIES | |
| EP3604518A4 (en) | ANTI-GPR20 ANTIBODY |